Reid Merryman, MD

Reid Merryman, MD, discusses which patients are typically monitored for minimal residual disease and whether there are specific subtypes or stages where the assessment is particularly critical.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.